Navigation Links
Sangamo BioSciences Announces Third Quarter 2011 Conference Call and Webcast
Date:10/18/2011

RICHMOND, Calif., Oct. 18, 2011 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced that the company will release its third quarter 2011 financial results on Tuesday, October 25, 2011, after the market closes. The press release will be followed by a conference call at 5:00 p.m. ET, which will be open to the public via telephone and webcast. During the conference call, the company will review the financial results and discuss other business matters.

The conference call dial-in numbers are 877-377-7553 for domestic callers and 678-894-3968 for international callers. The passcode for the call is 20389876.  Participants may access the live webcast via a link on the Sangamo BioSciences website in the Investors section under "Events and Presentations" http://investor.sangamo.com/events.cfm. For those unable to listen in at the designated time, a conference call replay will be available for one week following the conference call, from approximately 8:00 p.m. ET on October 25, 2011 to midnight ET on November 1, 2011. The conference call replay numbers for domestic and international callers are 855-859-2056 and 404-537-3406 respectively. The conference ID number for the replay is 20389876.

About Sangamo

Sangamo BioSciences, Inc. is focused on research and development of ZFP Therapeutics®, novel DNA-binding proteins for therapeutic gene regulation and modification. Sangamo has a Phase 1/2 clinical trial and two ongoing Phase 1 clinical trials to evaluate safety and clinical effect of a treatment for HIV/AIDS as well as a Phase 1 trial of a treatment for recurrent glioblastoma multiforme. Other therapeutic development programs are focused on Parkinson's disease, monogenic diseases, neuropathic pain and nerve regeneration.  Sangamo's core competencies enable the engineering of a
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Sangamo BioSciences Announces Presentation at the 18th Annual Newsmakers in the Biotech Industry Conference
2. Sangamo BioSciences Announces Presentation at the 2011 UBS Global Life Sciences Conference
3. Sangamo BioSciences Reports Second Quarter 2011 Financial Results
4. Sangamo BioSciences Announces Efficient Generation of Transgenic Pigs Using Zinc Finger Nuclease (ZFN) Technology
5. Sangamo BioSciences Announces Second Quarter 2011 Conference Call and Webcast
6. Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences
7. Sangamo Announces Pricing of Public Offering of Common Stock
8. Sangamo Announces Public Offering of Common Stock
9. Sangamo BioSciences and CHDI Foundation Announce Collaboration to Develop ZFP Therapeutic® for Huntingtons Disease
10. Sangamo BioSciences Announces Presentation at the 10th Annual Needham Healthcare Conference
11. Sangamo BioSciences Reports Fourth Quarter and Full Year 2010 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... 2013 As the R&D sector ... within the industry to deliver better products, faster. ... pharma companies often means turning big ideas into ... in collaboration with Sensidose AB and Recipharm, is ... products to market sooner. The partnership resulted in ...
(Date:5/21/2013)... 21, 2013  MacroGenics, Inc. today announced that ... (MGAH22), an Fc-modified chimeric monoclonal antibody (MAb), in ... oncoprotein," will be presented at the 2013 Annual ... during the Developmental Therapeutics - Immunotherapy Oral Abstract ... 4:30 PM.  The presentation will describe the results ...
(Date:5/21/2013)... Bed bugs have become so widespread in the ... turn to chemical-based pesticides for help to completely get rid ... those solutions present, the company advised the public to ... , According to My Cleaning Products, chemical-based pesticides are not ... It shared that the pests have already developed immunity to ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 Inflamax ... of the ITN to design the study, which ... two key clinical models used in the study ... and Nasal Allergen Challenge (NAC) models. Although both ... numerous publications, to date no direct comparison between ...
Breaking Biology Technology:The Development of an Innovative Microtablet Dosage Form, a Success Story: Live Webinar Hosted by Xtalks 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3New Guide to Kill Bed Bugs Published by My Cleaning Products, Company Enumerates Non-Toxic Means to Clear the Pests 2New Guide to Kill Bed Bugs Published by My Cleaning Products, Company Enumerates Non-Toxic Means to Clear the Pests 3Inflamax Research selected by the Immune Tolerance Network and the National Institutes of Health to conduct a landmark clinical study on the underlying mechanisms of allergic inflammation. 2
... Importance of Allergy Testing in Managing Chronic ... ... Phadia US Inc. announced today,that The National Asthma Education and Prevention ... for the Diagnosis and,Management of Asthma. Information in the guidelines reported ...
... steps ... towards public reporting status., SAN ANTONIO, Aug. 30 ... targeted cancer therapies with improved efficacy and reduced toxicity,announced the ... a control position in a public reporting shell company. ...
... Aug. 30 Pressure,BioSciences, Inc. (Nasdaq: ... has been,issued its first patent by the ... Biomolecular Complexes" (Number,2,259,318), this issuance extends the ... patents previously issued in the United States,Japan, ...
Cached Biology Technology:Updated NIH Guidelines Offer Valuable Information on Asthma Diagnosis and Management 2OncoVista, Inc. Closes on $6.8 Million Financing and Acquires Control of a Public Shell Company 2Pressure BioSciences, Inc. Issued First Patent in Canada 2Pressure BioSciences, Inc. Issued First Patent in Canada 3
(Date:5/21/2013)... is an uphill battle? Try staying fit in space, ... muscle and bone. , That,s the challenge a group ... new three-year, $1.2 million grant from NASA. Their goal ... exploratory missions. , "You could give astronauts the best ... them to stick to it, it isn,t going to ...
(Date:5/21/2013)... Royal Philips Electronics (NYSE: PHG, AEX: PHIA) ... ultrasound with Philips, industry leading Live 3D TEE, now ... with available Live 3D TEE and ICE will be ... EuroPCR, official meeting for the European Association of Percutaneous ... launch in 2012, Philips CX50 xMATRIX has been the ...
(Date:5/20/2013)... The Amazon rain forest, popularly known as the lungs of ... use carbon dioxide from the air to grow parts that ... away by the region,s plentiful rainfall. , Until recently ... the Amazon River and ended up deep in the ocean. ... exhale huge amounts of carbon dioxide though left open ...
Breaking Biology News(10 mins):Fueling fitness on the final frontier 2Philips CX50 xMATRIX now offers world-class interventional and diagnostic features on single portable system 2Amazon River exhales virtually all carbon taken up by rain forest 2Amazon River exhales virtually all carbon taken up by rain forest 3
... Kimmel Award for Innovative Investigation on Monday, Nov. 5 at ... grant of a million dollars over five years. Taking ... the impulses that drive evolution. Living cells are, from this ... have all sorts of interesting consequences for many other molecules ...
... all" when it comes to weight loss through exercise, says ... Neil King, from QUT,s Institute of Health and Biomedical Innovation, ... with the University of Leeds in the UK, which has ... of Obesity. "When it comes to losing weight, a ...
... issue of BioScience describes the history and summarizes the ... surface and substrate. , Although more expensive to construct ... energy costs during a buildings lifetime and control storm-water ... structures are currently less common in the United States ...
Cached Biology News:Weizmann Institute scientists discover: A 'risk distribution law' for evolution 2Weight loss -- not one size fits all 2
Normal human serum collected off the clot from healthy normal humans. Each donor unit is negative for anti-HIV 1&2, HIV-Ag, HCV, and HBsAg by FDA required tests...
sterile filtered, off the clot, all male donors, Total Protein: 4.5 to 8.5 g/dl...
Recombinant Mouse MMP-9, CF...
Human/Mouse/Rat JNK Pan Specific Affinity Purified PAb...
Biology Products: